(Bloomberg) -- Viking Therapeutics Inc. shares surged after its dual-action obesity shot helped patients lose weight and keep it off, even after they cut their dosing schedule in a small, exploratory study. Most Read from Bloomberg Paramount to Settle Lawsuits, Paving Way for Warner Bros. Qatar Energy Chief Says Bessent 'Wrong' About Hormuz Future Stocks Jump on AI Optimism as AMD Tops $1 Trillion: Markets Wrap AI Risk Is Everywhere and It's Making Billion Dollar Funds Nervous US and China Hail Talks as Positive Ahead of Trump-Xi Summit The company took an usual approach to analyzing the study, which was designed to identify the best dose of the drug that uses two different pathways to control weight.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.